Clinical Trials Directory

Trials / Unknown

UnknownNCT04428827

Outcome of Patients With Primary Aldosteronism

Long-term Outcomes in Patients With Primary Aldosteronism After Treatment

Status
Unknown
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
Changi General Hospital · Academic / Other
Sex
All
Age
14 Years – 100 Years
Healthy volunteers

Summary

Majority of patients with hypertension have primary hypertension (without an underlying cause). Primary aldosteronism (PA) is the most common cause of secondary hypertension, and can be found in 5-10% of patients locally. PA is caused by excessive release of a hormone (aldosterone) from the adrenal glands, which can be unilateral (one gland) or bilateral (both glands). It has been shown that excess aldosterone has other harmful effects in addition to hypertension, such as directly affecting the heart, blood vessels, kidneys, leading to increased cardiovascular morbidity and mortality. This is supported by studies showing reversal of these effects after treatment for PA. The investigators aim to assess the long-term cardiovascular, and renal outcomes of patients with PA, compared to patients with essential hypertension.

Conditions

Interventions

TypeNameDescription
PROCEDUREUnilateral adrenalectomy in patients with unilateral diseaseUnilateral adrenalectomy in patients with unilateral disease

Timeline

Start date
2016-10-01
Primary completion
2022-07-30
Completion
2022-07-30
First posted
2020-06-11
Last updated
2021-08-12

Locations

1 site across 1 country: Singapore

Source: ClinicalTrials.gov record NCT04428827. Inclusion in this directory is not an endorsement.